Treatment outcomes of MDR-TB and HIV co-infection in Europe

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F17%3AN0000057" target="_blank" >RIV/00064190:_____/17:N0000057 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1183/13993003.02363-2016" target="_blank" >http://dx.doi.org/10.1183/13993003.02363-2016</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1183/13993003.02363-2016" target="_blank" >10.1183/13993003.02363-2016</a>

Result language
angličtina
Original language name
Treatment outcomes of MDR-TB and HIV co-infection in Europe
Original language description
The ongoing HIV epidemic and the increasing number of patients with drug-resistant tuberculosis (TB) are seriously hampering global TB-control activities, including those in the World Health Organization (WHO) Region Europe. Overall, the prevalence of HIV co-infection in TB patients increased from 3.4% in 2008 to 8% in 2014 in the region. The prevalence of multidrug-resistant (MDR)-TB (drug resistance against at least isoniazid and rifampicin) reported for Europe – 15% in newly diagnosed TB patients and 48% in previously treated TB patients – is the highest in the world.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30203 - Respiratory systems

Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)